DLBCL - FOI Response Register

FoI Number
2024-204
Subject
DLBCL
Date Received
09/07/2024
Request and Response
  1. In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)?

Zero

1a. Of these patients, how many commenced treatment at your trust within the last 6 months?

Zero

  1.  In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:
  • R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)
  • R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)
  • Pola-BR (polatuzumab vedotin with rituximab and bendamustine)
  • Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone)
  • R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate)
  • R-IVAC (rituximab, ifosfamide, etoposide and cytarabine)
  • Axicabtagene ciloleucel (Yescarta)
  • Tisagenlecleucel
  • Epcoritamab
  • Loncastuximab tesirine
  • Glofitamab
  • Any other SACT
  • Stem cell transplant or bone marrow transplant (autologous or allogeneic)

Zero

  1. In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL):
  • Axicabtagene ciloleucel (Yescarta)
  • Tisagenlecleucel
  • Pola-BR (polatuzumab vedotin with rituximab and bendamustine)
  • Stem cell transplant or bone marrow transplant (autologous or allogeneic)
  • Any other treatments

Zero

  1. In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments:
  • CAR-T Therapy (E.g. Axicabtagene ciloleucel)
  • Stem cell transplant or bone marrow transplant (autologous or allogeneic)
  • Any other treatment

In accordance with FOISA s 17(1), NHS Shetland confirms that it does not hold the information requested. The information is not available.

5.   Do you participate in any active clinical trials for Diffuse Large B-Cell Lymphoma (DLBCL)? If so, can you please provide the name of each trial along with the number of patients taking part or enrolling?

No